TABLE 9

Potential therapeutic application of EP₄ agonists

Agonist	Route	Dose	Species	Experimental Model	Indication	Reference
3,7-Dithia PGE₁ and its isopropyl ester	Topical	0.01–0.1%	Monkey	“Glaucomatous” monkey intraocular pressure	Glaucoma	Woodward et al., 2009
4819-CD	Subcutaneous	0.3 mg/kg	Mouse	Ischemia-reperfusion injury	Myocardial infarction	Xiao et al., 2004
AEI-734					Colitis	Kabashima et al., 2002
AGN 205203 and its methyl ester	Subcutaneous	3 mg/kg	Mouse	Dextran sodium sulfate colitis	Colitis	Jiang et al., 2007
CP-734432	Subcutaneous	0.3–3 mg/kg	Rat	Ovariectomized rats	Osteoporosis	Ke et al., 2006
ONO-4819	Subcutaneous	10, 30 μg/kg	Rat	Femoral drill-hole injury	Bone fracture healing, osteoporosis	Tanaka et al., 2004
ONO-4819	Subcutaneous	3, 30 μg/kg	Rat	Mechanical loading, to tibia	Bone fracture, osteoporosis	Hagino et al., 2005
ONO-4819	Intravenous	100 ng/kg	Rat	Ovariectomized rat	Osteoporosis	Yoshida et al., 2002
ONO-AE1-329	Intracolonic	25, 100 μg/kg	Rat	Dextran sodium sulfate colitis	Colitis	Nitta et al., 2002
ONO-AE1-329	Intravenous	1–10 μg/kg	Rat	Indomethacin-induced lesions	NSAID-induced gastrointestinal lesions	Kunikata et al., 2002
ONO-AE1-329	Intraperitoneal	0.1 mg/kg	Rat	Indomethacin-induced lesions	NSAID-induced gastrointestinal lesions	Hatazawa et al., 2006
ONO-AE1-329	Subcutaneous	0.1–1000 ng/g	Rat	Neonatal ductus arteriosus dilatation	Premature birth	Momma et al., 2005
ONO-AE1-329	Local gelatin plug	1 mg/ml	Guinea pig	Auditory brain stem response	Sensorineural hearing loss	Hori et al., 2009
ONO-AE1-329	Subcutaneous	0.05, 0.5 mg/kg 55 μg daily infusion per animal	Mouse	N2 receptor knockout mice	Nephrogenic diabetes insipidus	Li et al., 2009
ONO-AE1-329	Subcutaneous	100 μg/kg	Mouse	Anti-glomerular basement membrane antibody nephritis	Glomerulonephritis	Nagamatsu et al., 2006
ONO-AE1-329	Intravenous	1–10 μg/kg	Rat	Endotoxin	Septicemia	Sakamoto et al., 2004
PF-04475270	Topical	0.002–0.1 mg/ml	Dog	Normal dog intraocular pressure	Glaucoma	Prasanna et al., 2009